Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
KPV3 residuesKPVEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: alpha-MSH(11-13), α-MSH C-terminal tripeptide
Three amino acids. That's the entire molecule. The KPV peptide (Lysine-Proline-Valine) is a tripeptide fragment from the tail end of alpha-melanocyte stimulating hormone, and it shuts down NF-kB, the master switch behind gut inflammation. Mouse colitis models show it enters inflamed intestinal cells through the PepT1 transporter, which gets upregulated in damaged tissue. No human clinical trial has been completed. Zero. But the preclinical mechanism is clean, community reports across IBD and IBS forums track closely with the animal data, and it's one of the few peptides that works orally for gut-specific conditions. Most users run 8-week cycles at 200 to 500 mcg per day subcutaneous or 500 to 1,500 mcg oral.
KPV (Lysine-Proline-Valine, CAS 67727-97-3) is the C-terminal tripeptide of alpha-melanocyte stimulating hormone and one of the most discussed anti-inflammatory peptides in the gut health community. It doesn't bind melanocortin receptors the way full-length alpha-MSH does. Instead, it enters cells through PepT1, a di/tripeptide transporter expressed in the small intestine. The targeting gets interesting during active inflammation. PepT1 expression increases in inflamed colonic epithelium, confirmed in both Caco2-BBE cell lines and mouse colitis models (Dalmasso et al., Gastroenterology 2008)[1]. Inflamed tissue absorbs more KPV than healthy tissue. Once inside the cell, KPV inhibits NF-kB nuclear translocation at nanomolar concentrations, cutting production of TNF-alpha, IL-1beta, IL-6, and IL-8. Community use mirrors the preclinical rationale almost exactly. Oral dosing at 500 to 1,500 mcg per day on an empty stomach is the standard protocol for IBD, IBS, and leaky gut. Subcutaneous injection at 200 to 500 mcg per day covers systemic inflammation. The BPC-157 stack is the most discussed combination; KPV handles the inflammatory signaling while BPC-157 drives mucosal repair. Multiple integrative medicine clinics recommend this pairing. The honest limitation: every dose recommendation comes from mouse data extrapolation and community trial-and-error. No human pharmacokinetic study has measured oral bioavailability. No dose-finding trial has been completed. The plasma half-life (~30 minutes) is estimated from alpha-MSH family kinetics, not from direct KPV measurement. Fifteen PubMed papers cover this peptide. The FDA has stated it lacks human exposure data for any administration route. That gap between clean preclinical science and absent human validation defines where KPV sits right now.
KPV bypasses melanocortin receptors entirely. Unlike full-length alpha-MSH, this tripeptide enters cells through PepT1, a proton-coupled transporter that normally imports dietary dipeptides and tripeptides across intestinal epithelium. PepT1 expression is low in healthy colonic tissue but climbs during active inflammation [1]. That upregulation creates a built-in targeting system. Inflamed epithelial cells, macrophages, and immune cells absorb KPV preferentially. Dalmasso and colleagues confirmed this uptake in Caco2-BBE intestinal cells and in mouse colitis models. Once inside the cell, KPV blocks NF-kB activation at nanomolar concentrations. It prevents the nuclear translocation of this transcription factor, which sits upstream of most inflammatory cytokine production. The downstream effect: reduced TNF-alpha, IL-1beta, IL-6, and IL-8 output. MAP kinase signaling is also suppressed. Anti-inflammatory IL-10 stays intact or increases. KPV also reduces adhesion molecule and chemokine receptor expression on immune cells. Fewer inflammatory cells migrate to damaged tissue. In colonic epithelium specifically, it decreases epithelial apoptosis and helps restore barrier integrity. Hyaluronic acid-functionalized nanoparticles loaded with KPV showed even greater colitis reduction in a 2017 study (Xiao et al., Mol Ther)[2]. The functional anti-inflammatory window extends well past the ~30 minute plasma half-life. Intracellular NF-kB suppression persists for 4 to 6 hours after uptake, which is why once-daily dosing works despite rapid plasma clearance.
Preclinical-only evidence. KPV inhibits NF-κB and suppresses pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in mouse colitis models via PepT1-mediated cellular uptake. Zero completed human clinical trials. No human PK, dose-finding, or efficacy data exist.
Gastroenterology 2008 (PMID 18061177): PepT1-mediated KPV uptake reduces intestinal inflammation in mouse colitis model
No human trials. All dose estimates are extrapolated from rodent data. No human PK study: half-life (~30 min) is inferred from α-MSH family literature. FDA explicitly states no human exposure data for any administration route.
Used primarily for gut inflammation (IBD, IBS, Crohn's, UC, leaky gut). Oral route preferred for GI-specific use based on PepT1 rationale. Slow onset (4–8 weeks); not an acute pain reliever. Generally well-tolerated. Sourcing quality is the main practical concern.
Community use closely mirrors the preclinical rationale: PepT1-targeted oral delivery for gut inflammation, NF-κB suppression over weeks. The mechanism supports what the community is doing, but the dosing is entirely extrapolated: no human trial confirms efficacy, optimal dose, or safety. Alignment is on mechanism/route logic, not on validated clinical outcomes.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 200mcg | Daily |
| Moderate | 500mcg | Daily |
| Aggressive | 1mg | Daily |
Start with the oral route if your goal is gut inflammation. The PepT1 transporter preferentially absorbs KPV in inflamed intestinal tissue, which is the whole point for IBD, IBS, and colitis. Reconstitution math for injectable: a 5 mg vial with 2 mL bacteriostatic water gives you 2,500 mcg/mL. For a 200 mcg dose, pull 8 units on a U-100 insulin syringe. For 500 mcg, pull 20 units. Oral dosing requires 2 to 3 times the subcutaneous dose. A 500 mcg oral dose delivers less active peptide to systemic circulation than 500 mcg subcutaneous. Account for GI degradation. Take oral KPV 30 minutes before food on an empty stomach. Dietary dipeptides compete at the PepT1 transporter, and eating too soon reduces uptake. The thing most beginners miss: this is not a fast-acting anti-inflammatory. KPV suppresses NF-kB upstream, not prostaglandin synthesis like NSAIDs. Expect 4 to 6 weeks for meaningful improvement. Running less than 4 weeks probably won't show you the full picture.
No long-term human safety data exists for KPV at any dose or route. The FDA explicitly stated it lacks human exposure information to assess safety. Cycling limits cumulative exposure duration pending human trial data. No receptor desensitization or antibody formation mechanism has been identified for KPV specifically.
Or use the universal Peptide Calculator for any peptide.
Expected: Reduced gut pain, improved stool consistency, decreased bloating by weeks 3–4; meaningful flare reduction and mucosal healing by weeks 6–8.
Monitor: Track stool consistency, pain scores, bloating frequency. Fecal calprotectin useful if accessible. Improvement should be detectable by week 6.
Gather supplies: 5 mg KPV vial, 2 mL bacteriostatic water, alcohol swabs, U-100 insulin syringe (29 or 30 gauge, 0.5 inch needle).
Draw 2 mL bacteriostatic water and inject slowly into the KPV vial, directing the stream against the glass wall. Do not shake. Swirl gently until the powder dissolves completely.
For common doses: 200 mcg equals 8 units on a U-100 syringe; 250 mcg equals 10 units; 500 mcg equals 20 units; 1,000 mcg equals 40 units.
For subcutaneous injection: pinch a fold of skin on the abdomen or outer thigh. Insert the needle at a 45-degree angle. Inject slowly and hold for 5 seconds before withdrawing. Rotate injection sites daily.
For oral use: draw the desired dose into a syringe (no needle), squirt into the mouth and swallow on an empty stomach. Alternatively, use pre-made oral capsules if available. Take 30 minutes before food.
For the advanced flare protocol (1,000 mcg total), split into 500 mcg morning and 500 mcg evening, 8 to 12 hours apart.
Store reconstituted vial in the refrigerator at 2 to 8 degrees Celsius. Use within 4 weeks of reconstitution.
2–3× the SC dose required (500–1,500 mcg/day oral vs. 200–500 mcg/day SC) due to partial GI degradation and transit losses. PepT1 upregulation in inflamed tissue enhances intestinal uptake: a natural targeting mechanism.
Take on empty stomach (30 min pre-meal) to reduce competitive inhibition at PepT1 transporter by dietary dipeptides. No human oral bioavailability study exists: dose recommendation is mechanistically supported but empirically unvalidated.
200–500 mcg/day (beginner–moderate); 500–1,000 mcg/day split doses (advanced/acute flare). Near-complete SC absorption assumed.
Provides systemic inflammatory coverage: skin, joints, gut (systemically). Does not provide the PepT1-targeted local GI delivery advantage of oral route.
Topical application studied in psoriasis, dermatitis, wound healing research. No established community dosing: iontophoresis delivery explored in published literature (ScienceDirect); not currently a standard community protocol.
Topical route is NOT listed in current peptides.ts administrationRoute field. Published evidence for iontophoresis and microneedle delivery exists: primarily for localized skin anti-inflammatory effect. Community use via raw peptide in a cream base is occasionally reported but lacks standardization.
Some community users report sublingual spray as providing "more systemic" effect than oral capsule. No bioavailability data. Dose typically mirrors SC dose (200–500 mcg).
Bitter taste commonly reported with sublingual spray. No formal comparison to oral capsule or SC injection.
Complementary gut repair mechanism: KPV suppresses inflammatory signaling (NF-κB), BPC-157 drives mucosal tissue repair and angiogenesis. Most discussed KPV stack; recommended by integrative medicine clinics for IBD/IBS.
KPV 500 mcg + BPC-157 500 mcg, both oral or both SC, daily: 8 weeks. Oral co-administration popular for injection-averse users.
Immune modulation for chronic gut infection component: LL-37 provides antimicrobial/antifungal coverage while KPV reduces inflammatory cytokine cascade. Stack discussed in SIBO and chronic gut dysbiosis contexts.
KPV 500 mcg SC daily + LL-37 100–200 mcg SC daily: 4–6 weeks. Not for beginners; use with caution re: additive immune effects.
Skin inflammation stack: GHK-Cu promotes collagen synthesis and tissue repair while KPV reduces local inflammatory signaling. Discussed for psoriasis, eczema, and wound healing.
KPV 500 mcg SC daily + GHK-Cu topical or 1–2 mg SC 3x/week: 6–8 weeks.
Systemic healing and anti-inflammatory stack: TB-500 promotes actin polymerization and tissue repair; KPV adds NF-κB suppression. Used in the "quad gut/healing stack" (BPC-157 + TB-500 + KPV + GHK-Cu).
KPV 500 mcg SC daily + TB-500 5 mg SC 2x/week loading, then 2.5 mg 2x/week maintenance.
Potential additive immune suppression/modulation. KPV suppresses inflammatory cytokines; TA-1 is an immune stimulator/modulator. Stacking may create unpredictable immune signaling, especially risky in autoimmune conditions. Limited interaction data.
Potential additive immunosuppressive effect. KPV reduces TNF-α, IL-1β, IL-6: the same targets as many IBD biologics. Combined use without physician oversight risks over-suppression of immune response and increased infection risk.
Do not combineOverlapping anti-inflammatory pathways. Both suppress NF-κB and inflammatory cytokines via different mechanisms. No direct interaction data; monitor for additive immune suppression in combined use.
Pricing updated 2026-04-09
The biggest safety concern with KPV is the unknown. Zero completed human clinical trials exist. No human pharmacokinetic data. No dose-finding study. The FDA has explicitly stated it lacks human exposure information for any administration route. Every safety profile below comes from preclinical research and community reporting, not from controlled human trials. That said, the community tolerability signal is remarkably clean. Most users report no side effects at standard doses (200 to 500 mcg subcutaneous, 500 to 1,500 mcg oral). KPV is a naturally occurring tripeptide fragment, three amino acids long, which limits the immunogenicity risk that larger synthetic peptides carry. Herxheimer-like reactions in weeks 1 to 2. This is the most commonly reported negative experience, specifically among IBD and Crohn's patients. Gut symptoms temporarily worsen before improving. The community explanation is that rapid NF-kB suppression shifts the inflammatory milieu. Slow titration from 250 mcg manages this in most cases. Injection site reactions with subcutaneous administration. Mild redness and irritation at the injection site, consistent with other peptide injections. KPV has a short plasma half-life (~30 minutes), so daily injection site rotation across abdomen and thigh areas is the standard recommendation. If irritation persists despite rotation, switching to oral dosing is the typical approach. Potential immune over-suppression with concurrent medications. KPV reduces TNF-alpha, IL-1beta, and IL-6, the same cytokine targets as many IBD biologics (infliximab, adalimumab) and immunosuppressants (methotrexate, azathioprine). Stacking KPV with these medications without physician oversight risks additive immune suppression and increased infection susceptibility. This is the one genuinely serious risk in the community use pattern. Oral-specific: mild bitter taste reported with sublingual spray formulations. Some users note transient GI discomfort at higher oral doses (above 1,000 mcg), though this typically resolves within the first week. No hepatotoxicity, nephrotoxicity, or cardiovascular effects have been reported in preclinical literature or community use. No antibody formation or receptor desensitization mechanism has been identified. Pregnancy and breastfeeding: no safety data exists. Do not use. This applies to both oral and injectable forms. Children and adolescents under 18: not studied in any context. No pediatric dosing exists. Active malignancy: KPV suppresses immune surveillance pathways (NF-kB, inflammatory cytokines). Effects on tumor immune response have not been studied. Avoid until data exists. When to stop: if gut symptoms worsen and persist beyond the 2-week titration window, discontinue or reduce dose. If you experience signs of immune suppression (frequent infections, slow wound healing), stop immediately and consult a physician. If injection site reactions do not resolve with rotation, switch to oral or discontinue.
Verify KPV dosing and safety with a second opinion
No FDA-approved formulation exists. KPV was on the FDA Category 2 list until April 15, 2026. PCAC review begins July 2026. All available product is research-chemical gray market with wide purity range. Vendors below ~$35/5mg vial typically lack HPLC or mass-spec documentation.
| Test | When | Target |
|---|---|---|
| Fecal calprotectin | Baseline and week 6–8 | <50 µg/g (normal); <200 µg/g (clinical remission threshold for IBD) |
| C-reactive protein (CRP) / hsCRP | Baseline and week 6 | <1.0 mg/L (optimal); <3.0 mg/L (acceptable) |
| Complete blood count (CBC) with differential | Baseline; repeat at week 8 if concurrent immunosuppressant use | — |
| ESR (erythrocyte sedimentation rate) | Optional: baseline and week 8 | — |
| Subjective symptom diary (pain, stool consistency, bloating frequency) | Weekly throughout protocol | — |
Quantitative marker of intestinal inflammation: most direct measure of KPV gut efficacy. Elevated in UC and Crohn's; should decrease with effective treatment.
Systemic inflammatory marker. Less gut-specific than calprotectin but broadly useful. Should decrease with KPV's NF-κB suppression.
Monitor for immune modulation effects, especially lymphocyte and neutrophil counts, if stacking with LL-37 or TA-1, or if on concurrent IBD medications.
Secondary systemic inflammatory marker; less sensitive than CRP but useful corroboration.
Most practical tracking tool in absence of labs. Establishes trend; useful to determine response before labs are ordered.
Body adjusts to the peptide. Some users report reduced bloating and mild improvement in GI comfort within the first week. Establish consistent daily dosing routine.
Anti-inflammatory effects become noticeable. Reduced gut pain, improved stool consistency, and decreased bloating reported by most users. Inflammatory markers may begin to improve.
Significant reduction in gut inflammation symptoms. Users with colitis or IBS typically report meaningful improvement in flare frequency and severity. Mucosal healing is underway.
Peak therapeutic benefit for most users. Gut barrier integrity improves. Systemic inflammatory markers (CRP, calprotectin) often show measurable reduction. Skin inflammation also improves if present.
Maintenance phase. Most protocols recommend cycling off after 8 weeks. Benefits typically persist for several weeks after discontinuation. Repeat cycles as needed for flare management.
Weeks 1 to 2, Tolerance establishment. Your body is adjusting. KPV begins entering inflamed intestinal cells via PepT1 uptake, and NF-kB suppression starts at the cellular level. Don't expect visible results yet. Some users notice subtle bloating reduction in the first week. IBD patients may experience a Herxheimer-like flare, where symptoms temporarily worsen before improving. Mild injection site redness is normal with subcutaneous dosing; higher oral doses can cause transient GI discomfort. Slow titration from 250 mcg manages the Herxheimer response. Weeks 2 to 4, Early anti-inflammatory effect. Sustained NF-kB suppression begins reducing downstream cytokine production. TNF-alpha, IL-1beta, and IL-6 output should be falling. Most users report reduced gut pain, improved stool consistency, and less frequent bloating during this window. CRP levels may start normalizing. Side effects from the first two weeks typically resolve. Some oral users mention a mild bitter taste with sublingual spray. Weeks 4 to 6, Meaningful inflammation reduction. Preclinical models show measurable intestinal inflammation reduction by this point. Epithelial apoptosis decreases and barrier integrity starts recovering. Community reports align: IBD and IBS flare frequency and severity drop noticeably. Users treating skin conditions (psoriasis, eczema) alongside gut inflammation also report visible improvement. Weeks 6 to 8, Peak therapeutic benefit. Full mucosal healing and barrier restoration in preclinical models. CRP and fecal calprotectin often show measurable decreases. Most IBD users describe meaningful quality-of-life improvement by now. Skin anti-inflammatory effects become visible. Some users extend to 10 or 12 weeks if they're responding well and tolerating the peptide. Weeks 8 and beyond, Cycling off and maintenance. No long-term human data exists. Preclinical models suggest anti-inflammatory effects persist after discontinuation; no receptor desensitization has been identified. Community reports confirm benefits lasting several weeks after the cycle ends. Standard recommendation: 4 to 8 week break, then repeat if needed. Some users run a 5-on, 2-off weekly pattern for extended maintenance.
KPV uptake via PepT1 begins in inflamed tissue; NF-κB suppression initiates. No measurable clinical endpoint expected this early.
Subtle reduction in bloating reported by some users. Herxheimer-like reactions possible in IBD patients (worsening before improvement). Most report little to no change.
Sustained NF-κB suppression should begin reducing downstream cytokine production (TNF-α, IL-1β, IL-6). Mucosal inflammation reduction starts.
Reduced gut pain, improved stool consistency, decreased bloating reported by majority. Inflammatory markers (CRP) may begin to normalize.
Significant reduction in intestinal inflammation in mouse models by this point. Epithelial apoptosis reduced; barrier integrity improving.
Significant improvement in IBD/IBS flare frequency and severity. Skin inflammation (psoriasis, eczema) also improving in users treating both conditions.
Full mucosal healing and barrier restoration in preclinical models. Systemic inflammatory markers (CRP, calprotectin) measurably reduced.
Peak benefit period. Most IBD users report meaningful quality-of-life improvement. Skin anti-inflammatory effects visible. Some users extend to 10–12 weeks if responding well.
No long-term human data. Preclinical: anti-inflammatory effects persist post-discontinuation. No receptor desensitization mechanism identified.
Benefits reported to persist several weeks after cycle ends. Most protocols recommend 4–8 week break then repeat if needed. 5-on/2-off weekly cycling used by some for extended maintenance.
Source: Estimated from rapid plasma degradation kinetics of small tripeptides; KPV has a plasma half-life under 30 minutes but exerts prolonged intracellular effects via PepT1 uptake (PMID 18061177)
Loading the interactive decay curve.
KPV has no FDA approval for any indication. The FDA placed it on the Category 2 bulk drug substance list during the 2024 to 2025 enforcement period, prohibiting compounding pharmacies from producing it. On April 15, 2026, HHS removed KPV from Category 2 along with 11 other peptides. PCAC review begins July 2026. Compounding pharmacy access is not yet available and is projected for late 2026 to mid-2027. All currently available KPV product is sourced from research chemical suppliers. It is sold labeled "for research purposes only" and is not approved for human consumption by any regulatory agency. Quality varies widely between vendors. WADA status: KPV is not currently listed on the WADA prohibited substance list, but athletes should verify current status before use. This content is for informational and educational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any peptide. Do not use KPV as a substitute for prescribed IBD medications without physician guidance.
Peptide Schedule Research TeamReviewed Apr 202610 Citations
